Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.
Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies. Its technology platforms include exoSTAMP, designed for highly sensitive isolation and analysis of circulating exosomes, and exoSC, aimed at scalable manufacturing of exosome-based products.
The company maintains strategic collaborations with academic and clinical partners to accelerate development timelines and broaden the potential application of its technologies. These partnerships support Avalon’s efforts to optimize manufacturing processes, refine product specifications and initiate clinical trials in oncology and, potentially, viral diseases where cell therapy approaches can address unmet medical needs.
Founded in 2016 and publicly listed on NASDAQ under the ticker ALBT, Avalon GloboCare is led by Dr. Leem Chao, its Chairman and Chief Executive Officer. Under his leadership, the company has expanded its footprint across key biopharma hubs and continues to advance a diversified portfolio of innovative therapies and diagnostics designed to improve patient outcomes worldwide.
AI Generated. May Contain Errors.
Free ALBT Stock Alerts